(-)-SCR1693 Protects against Memory Impairment and Hippocampal Damage in a Chronic Cerebral Hypoperfusion Rat Model

Area of Science:

• Neuroscience
• Pharmacology
• Dementia Research

Background:

• Chronic cerebral hypoperfusion (CCH) is a primary cause of vascular dementia (VaD) and a factor in Alzheimer's disease (AD).
• CCH leads to significant cognitive decline and hippocampal neuronal loss.
• Currently, no approved pharmacological treatments exist for VaD.

Purpose of the Study:

• To investigate the therapeutic potential of a novel compound, (-)-SCR1693, for treating CCH-induced VaD.
• To evaluate the effects of (-)-SCR1693 on memory deficits and neuronal damage in a rat model of CCH.

Main Methods:

• A rat model of CCH was established using bilateral common carotid artery occlusion.
• The effects of (-)-SCR1693 on memory performance (water maze task) and hippocampal neuronal integrity were assessed.
• Cholinergic function and phospho-tau protein accumulation were analyzed.

Main Results:

• (-)-SCR1693 administration prevented memory deficits in rats subjected to CCH.
• The compound mitigated neuronal loss in the hippocampus.
• (-)-SCR1693 treatment rectified cholinergic dysfunction and reduced phospho-tau protein accumulation.

Conclusions:

• (-)-SCR1693 demonstrates significant therapeutic potential for treating vascular dementia induced by chronic cerebral hypoperfusion.
• The compound's ability to improve cognitive function and protect neurons suggests a novel treatment strategy for VaD.